- Home
- ASMB
as 07-26-2024 4:00pm EST
Assembly Biosciences Inc is a clinical-stage biotechnology company. It is advancing two innovative platform programs, a novel class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutics, which are designed to restore health to a dysbiotic microbiome. The company's HBV-cure program is aimed at increasing the current low cure rate for patients with HBV and is pursuing multiple drug candidates that inhibit multiple steps of the HBV lifecycle. Assembly has discovered several novel core protein Allosteric Modulators, which are small molecules that directly target and allosterically modulate the HBV core protein. The majority of the revenue is generated from the HBV cure program.
| Founded: | 2005 | Country: | United States |
| Employees: | N/A | City: | SOUTH SAN FRANCISCO |
| Market Cap: | 97.1M | IPO Year: | 2010 |
| Target Price: | N/A | AVG Volume (30 days): | 14.8K |
| Analyst Decision: | Hold | Number of Analysts: | 1 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -10.48 | EPS Growth: | N/A |
| 52 Week Low/High: | $7.68 - $20.04 | Next Earning Date: | 08-07-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | 20.00% |
Stock Insider Trading Activity of Assembly Biosciences Inc. (ASMB)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Schornstein Alexander | ASMB | 10% Owner | Jul 3 '24 | Buy | $12.52 | 4,438 | $55,563.76 | 693,113 | SEC Form 4 |
| Schornstein Alexander | ASMB | 10% Owner | Jul 3 '24 | Buy | $12.29 | 4,562 | $56,066.98 | 688,675 | SEC Form 4 |
| White Nicole S | ASMB | Chief Manufacturing Officer | May 23 '24 | Sell | $14.93 | 172 | $2,568.61 | 12,853 | SEC Form 4 |
| Bjorkquist Jeanette M | ASMB | Principal Accounting Officer | May 23 '24 | Sell | $14.93 | 24 | $358.41 | 3,142 | SEC Form 4 |
| Okazaki Jason A | ASMB | CEO and President | May 23 '24 | Sell | $14.93 | 549 | $8,198.66 | 16,082 | SEC Form 4 |
| McHutchison John G | ASMB | Director | May 23 '24 | Sell | $14.93 | 2,117 | $31,614.85 | 19,104 | SEC Form 4 |
| Okazaki Jason A | ASMB | CEO and President | Apr 29 '24 | Sell | $12.71 | 1,569 | $19,936.97 | 16,423 | SEC Form 4 |
| White Nicole S | ASMB | Chief Manufacturing Officer | Apr 29 '24 | Sell | $12.71 | 1,255 | $15,947.03 | 13,025 | SEC Form 4 |
| McHutchison John G | ASMB | Director | Apr 1 '24 | Sell | $13.07 | 1,206 | $15,764.71 | 21,221 | SEC Form 4 |
| Bjorkquist Jeanette M | ASMB | Principal Accounting Officer | Mar 29 '24 | Sell | $13.07 | 114 | $1,490.20 | 3,166 | SEC Form 4 |
| Okazaki Jason A | ASMB | CEO and President | Mar 29 '24 | Sell | $13.07 | 354 | $4,627.45 | 13,826 | SEC Form 4 |
| White Nicole S | ASMB | Chief Manufacturing Officer | Mar 29 '24 | Sell | $13.07 | 197 | $2,575.16 | 10,947 | SEC Form 4 |
| Okazaki Jason A | ASMB | CEO and President | Mar 27 '24 | Sell | $12.87 | 392 | $5,045.04 | 14,180 | SEC Form 4 |
| Schornstein Alexander | ASMB | 10% Owner | Jan 17 '24 | Buy | $0.78 | 299,994 | $235,195.30 | 7,864,286 | SEC Form 4 |
| Schornstein Alexander | ASMB | 10% Owner | Jan 17 '24 | Buy | $0.80 | 345,086 | $276,068.80 | 8,209,372 | SEC Form 4 |
| Schornstein Alexander | ASMB | 10% Owner | Nov 20 '23 | Buy | $0.72 | 300,000 | $215,400.00 | 7,464,292 | SEC Form 4 |
| Schornstein Alexander | ASMB | 10% Owner | Nov 20 '23 | Buy | $0.67 | 100,000 | $66,700.00 | 7,564,292 | SEC Form 4 |
Latest Assembly Biosciences Inc. News
ASMB Breaking Stock News: Dive into ASMB Ticker-Specific Updates for Smart Investing
Simply Wall St.
8 days ago
Investors in Assembly Biosciences (NASDAQ:ASMB) have unfortunately lost 90% over the last five years
GlobeNewswire
12 days ago
Assembly Biosciences Presents New Preclinical Data Highlighting Investigational Helicase-Primase Inhibitors at International Herpesvirus Workshop
Argus Research
18 days ago
Daily – Vickers Top Buyers & Sellers for 07/09/2024
GlobeNewswire
a month ago
Assembly Biosciences Doses First Participant in Phase 1b Clinical Trial Evaluating Next-Generation Capsid Assembly Modulator Candidate ABI-4334 for the Treatment of Chronic Hepatitis B Virus Infection
GlobeNewswire
a month ago
Assembly Biosciences Announces $12.6 Million in Equity Financings
GlobeNewswire
2 months ago
Assembly Biosciences Doses First Participant in Phase 1a/b Clinical Trial of Herpes Simplex Virus Helicase-Primase Inhibitor Candidate ABI-5366
GlobeNewswire
2 months ago
Assembly Biosciences Presents New Data Highlighting Hepatitis D Virus Entry Inhibitor ABI-6250 at the EASL Congress™ 2024
GlobeNewswire
2 months ago
Assembly Biosciences to Present Data at Upcoming International Herpesvirus Workshop and EASL Congress™ 2024
Compare ASMB vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ASMB Assembly Biosciences Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.